Simvastatin

Overview

Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. It is also used to decrease the risk of heart problems in those at high risk. It is taken by mouth.[1] WP

Common side effects include constipation, headaches, and nausea. Serious side effects may include muscle breakdown, liver problems, and increased blood sugar levels. A lower dose may be needed in people with kidney problems. There is evidence of harm to the developing baby when taken during pregnancy and it should not be used by those who are breastfeeding. It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver.[1][2] WP

Simvastatin is made from the fungus Aspergillus terreus. It was patented by Merck in 1980, and came into medical use in 1992. Simvastatin is available as a generic medication, and is on the World Health Organization's List of Essential Medicines. In 2023, it was the 22nd most commonly prescribed medication in the United States, with more than 24 million prescriptions.[1][3–7] WP

Uses, dosage and effects

Medical uses

The primary uses of simvastatin are to treat dyslipidemia and to prevent atherosclerosis-related complications such as stroke and heart attacks in those who are at high risk. It is recommended to be used as an addition to a low-cholesterol diet.[1] WP

In heart protection studies, simvastatin showed the ability to lower LDL cholesterol by about 1·5 mmol/L, which resulted in substantial reductions in mortality rates. Simvastatin also reduced the numbers of other events like heart attacks, strokes, and revascularizations and MI significantly.[8] WP

The Heart Protection Study evaluated the effects of simvastatin in people with risk factors including existing cardiovascular disease, diabetes, or stroke, but having relatively low LDL cholesterol. In this trial, which lasted 5.4 years, overall mortality was reduced by 13% and cardiovascular mortality was reduced by 18%. People receiving simvastatin experienced 38% fewer nonfatal heart attacks and 25% fewer strokes.[9] WP

Statins in general have been proposed as beneficial in reducing the progression of Age-related Macular Degeneration (AMD). Multiple observational studies have been conducted to analyse the benefits of statin use in delaying the progression of AMD but have resulted in conflicting outcomes. Given the current available information, simvastatin should not be recommended solely for the treatment of AMD.[10][11][12] WP⚠ Wikipedia itself has flagged this text: citation needed.

Risks and side effects

Contraindications

Simvastatin is contraindicated with pregnancy, breastfeeding, and liver disease. Pregnancy must be avoided while on simvastatin due to potentially severe birth defects. Patients cannot breastfeed while on simvastatin due to potentially disrupting the infant's lipid metabolism. High doses of simvastatin are also contraindicated with the widely used antihypertensive amlodipine. A lower dose is also recommended in people taking the calcium channel blockers, verapamil and diltiazem, as well as those taking amiodarone.[13–17] WP

Adverse effects

Common side effects (>1% incidence) may include indigestion and eczema. There is evidence to suggest that rare side effects such as joint pain, memory loss, and muscle cramps are more likely to occur in patients who take higher doses of simvastatin. Cholestatic hepatitis, hepatic cirrhosis, rhabdomyolysis (destruction of muscles and blockade of renal system), and myositis have been reported in patients receiving the drug chronically. Serious allergic reactions to simvastatin are rare.[9][13][18] WP

A type of DNA variant known as a single nucleotide polymorphism (SNP) may help predict individuals prone to developing myopathy when taking simvastatin; a study ultimately including 32,000 patients concluded the carriers of one or two risk alleles of a particular SNP, rs4149056, were at a five-fold or 16-fold increased risk, respectively. In 2012, the Clinical Pharmacogenetics Implementation Consortium has released guidelines regarding the use of rs4149056 genotype in guiding dosing of simvastatin and updated the guideline in 2014.[19–22] WP

In March 2012, the U.S. Food and Drug Administration (FDA) updated its guidance for statin users to address reports of memory loss, liver damage, increased blood sugar, development of type 2 diabetes, and muscle injury. The new guidance indicates:[23] WP

• FDA has found that liver injury associated with statin use is rare but can occur.[23] WP⚠ Wikipedia itself has flagged this text: citation needed.
• The reports about memory loss, forgetfulness, and confusion span all statin products and all age groups. The FDA says these experiences are rare, but that those affected often report feeling "fuzzy" or unfocused in their thinking.[23] WP⚠ Wikipedia itself has flagged this text: citation needed.
• A small increased risk of raised blood sugar levels and the development of type 2 diabetes have been reported with the use of statins. A 2010 published meta-analysis found for every 255 patients taking a statin for 4 years, one additional case of diabetes would occur whilst preventing 5.4 major coronary events.[24] WP
• Some drugs interact with statins in a way that increases the risk of muscle injury called myopathy, characterized by unexplained muscle weakness or pain.[23] WP⚠ Wikipedia itself has flagged this text: citation needed.

On 19 March 2010, the FDA issued another statement regarding simvastatin, saying it increases the risk of muscle injury (myopathy) when taken at high doses or at lower doses in combination with other drugs. The highest dose rate causes muscle damage in 610 of every 10,000 people in contrast to a lower dose, which causes muscle damage in eight of 10,000 people. The FDA warning, released again on 8 June 2011, suggested that high-dose "simvastatin should be used only in patients who have been taking this dose for 12 months or more without evidence of muscle injury" and that it "should not be started in new patients, including patients already taking lower doses of the drug".[15][25][26] WP

Interactions

Interactions

Simvastatin has important interactions with grapefruit juice and other drugs, including some that are commonly used for the treatment of cardiovascular disease. These interactions are clinically important because increasing simvastatin serum levels above those normally provided by the maximum recommended dose increases the risk of muscle damage, including the otherwise rare and potentially fatal side effect of rhabdomyolysis.[15] WP

Consuming large amounts of grapefruit juice increases serum levels of simvastatin by up to three-fold, increasing the risk of side effects. The FDA recommends that people taking statins should avoid consuming large quantities of grapefruit juice (more than 1 quart/946 ml) per day to reduce risk of myopathy.[15][27–30] WP

Simvastatin also interacts with other drugs, including some used to treat cardiovascular problems. It should not be taken by people who are also taking the antifungal drugs fluconazole, itraconazole, or posaconazole; the antibiotics erythromycin, clarithromycin, or telithromycin; HIV protease inhibitors; the antidepressant nefazodone; the cardiovascular drug gemfibrozil; the immunosuppressant ciclosporin, or the endometriosis drug danazol. Reduced maximum doses of simvastatin apply for patients taking certain other drugs, including the cardiovascular drugs verapamil, diltiazem, amiodarone, amlodipine, and ranolazine.[15][31] WP

Pharmacology

Pharmacodynamics

All statins act by inhibiting 3-hydroxy-3-methylglutaryl (HMG) coenzyme A reductase. HMG-CoA reductase, the rate-limiting enzyme of the HMG-CoA reductase pathway, the metabolic pathway responsible for the endogenous production of cholesterol. Statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentration, but they are less effective than the fibrates in reducing triglyceride concentration. However, statins reduce cardiovascular disease events and total mortality irrespective of the initial cholesterol concentration. This is a major piece of evidence that statins work in another way than the lowering of cholesterol (called pleiotropic effects).[32] WP

Simvastatin is an effective serum lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50%. Simvastatin had been shown to interact with lipid-lowering transcription factor PPAR-alpha and that interaction might control the neurotrophic action of the drug.[33] WP⚠ Wikipedia itself has flagged this text: citation needed.

Pharmacokinetics

The drug is in the form of an inactive lactone that is hydrolyzed after ingestion to produce the active β-hydroxyacid form. Simvastatin is primarily metabolized by CYP3A4 yielding products which are also active HMG-CoA reductase inhibitors.[34] WP

History

History

The development of simvastatin was closely linked with lovastatin. Biochemist Jesse Huff and his colleagues at Merck began researching the biosynthesis of cholesterol in the early 1950s. In 1956, mevalonic acid was isolated from a yeast extract by Karl Folkers, Carl Hoffman, and others at Merck, while Huff and his associates confirmed that mevalonic acid was an intermediate in cholesterol biosynthesis. In 1959, the HMG-CoA reductase enzyme (a major contributor of internal cholesterol production) was discovered by researchers at the Max Planck Institute. This discovery encouraged scientists worldwide to find an effective inhibitor of this enzyme.[35][36] WP

By 1976, Akira Endo had isolated the first inhibitor, mevastatin, from the fungus Penicillium citrinium while working at Daiichi Sankyo in Japan. In 1979, Hoffman and colleagues isolated lovastatin from a strain of the fungus Aspergillus terreus. While developing and researching lovastatin, Merck scientists synthetically derived a more potent HMG-CoA reductase inhibitor from a fermentation product of A. terreus, which was designated MK-733 (later to be named simvastatin).[37][38] WP

In 1994, publication of the results of the Scandinavian Simvastatin Survival Study (4S) provided the first unequivocal evidence that lowering LDL cholesterol via statin treatment reduces cardiovascular events and overall mortality. A total of 4,444 people with coronary heart disease and blood cholesterol levels from 5.5 to 8.0 mmol/L were randomized to simvastatin treatment or placebo and followed for an average of 5 years. Compared to the placebo group, those treated with simvastatin experienced a 30% decrease in overall mortality, a 42% reduction in coronary death, a 34% reduction in major coronary events, and a 37% reduction in revascularization procedures.[39][40] WP

Legal status

Economics

Prior to losing US patent protection, simvastatin was Merck & Co.'s largest-selling drug.[41] WP

Under provisions of the Patient Protection and Affordable Care Act (PPACA) in the United States, health plans may cover the costs of simvastatin 10 mg, 20 mg, and 40 mg for adults aged 40–75 years based on United States Preventive Services Task Force (USPSTF) recommendations.[42][43][44] WP

Zocor had an original patent expiry date in December 2005, but was extended by the United States Patent and Trademark Office (USPTO) to expire in June 2006.[45] WP

Brand names

Simvastatin was initially marketed by Merck & Co under the brand name Zocor but is available generically in most countries following the patent expiry. A combination of simvastatin along with ezetimibe is sold under the brand name Vytorin and is jointly marketed by Merck and Schering-Plough. WP⚠ Wikipedia itself has flagged this text: citation needed.

Brand names include Zocor, Zocor Heart Pro, marketed by the pharmaceutical company Merck & Co., Simlup, Simvotin, Simcard (India), Denan (Germany), Liponorm, Sinvacor, Sivastin (Italy), Lipovas (Japan), Lodales (France), Zocord (Austria and Sweden), Zimstat, Simvahexal (Australia), Lipex (Australia and New Zealand), Simvastatin-Teva, Simvacor, Simvaxon, Simovil (Israel), available in Thailand under the brand Bestatin manufactured by Berlin Pharmaceutical Industry Co Ltd and others. WP⚠ Wikipedia itself has flagged this text: citation needed.

In July 2004, Zocor Heart Pro 10mg was made available over the counter in the UK. This decision was criticised by the Drug and Therapeutics Bulletin.[46][47][48] WP

Chemistry

Formula

C25H38O5 PC

CAS number

79902-63-9 PC

Molar mass (g/mol)

418.6 PC

IUPAC name (computed by PubChem)

[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate PC

SMILES

CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C PC

InChIKey

RYMZZMVNJRMUDD-HGQWONQESA-N PC

PubChem CID

54454

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Simvastatin
2. Other Prescribing medicines in pregnancy database. 3 March 2014
3. Other Cechinel-Filho V. Plant bioactives and drug discovery: principles, practice, and perspectives. 2012
4. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
5. Other WHO model list of essential medicines: 21st list 2019. 2019
6. Other Top 300 of 2023
7. Other Simvastatin Drug Usage Statistics, United States, 2014 - 2023
8. Journal / agency Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opinion on Pharmacotherapy. December 2004. doi:10.1517/14656566.5.12.2583 · PMID 15571475
9. Journal / agency Zocor Full Prescribing Information
10. Journal / agency Roizenblatt M, Naranjit N, Maia M, Gehlbach PL. The Question of a Role for Statins in Age-Related Macular Degeneration. International Journal of Molecular Sciences. November 2018. doi:10.3390/ijms19113688 · PMID 30469381 · PMC6274767
11. Journal / agency Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Cukras C, Ferris FL, Chew EY. The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9. Ophthalmology. December 2015. doi:10.1016/j.ophtha.2015.08.028 · PMID 26435335 · PMC4658271
12. Journal / agency Barbosa DT, Mendes TS, Cíntron-Colon HR, Wang SY, Bhisitkul RB, Singh K, Lin SC. Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005-2008. Eye. April 2014. doi:10.1038/eye.2014.8 · PMID 24503725 · PMC3983650
13. Other Zocor. 14 November 2012
14. Journal / agency Simvastatin
15. Journal / agency FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 8 June 2011
16. Journal / agency Simvastatin: updated advice on drug interactions - updated contraindications. Drug Safety Update. August 2012
17. Journal / agency FDA Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone. 15 December 2011
18. Other Baselt R. Disposition of Toxic Drugs and Chemicals in Man. 2008
19. Other rs4149056 - SNPedia
20. Journal / agency Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. The New England Journal of Medicine. August 2008. doi:10.1056/NEJMoa0801936 · PMID 18650507
21. Journal / agency Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clinical Pharmacology and Therapeutics. October 2014. doi:10.1038/clpt.2014.125 · PMID 24918167 · PMC4169720
22. Journal / agency Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clinical Pharmacology and Therapeutics. July 2012. doi:10.1038/clpt.2012.57 · PMID 22617227 · PMC3384438
23. Journal / agency FDA Expands Advice on Statin Risks
24. Journal / agency Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. February 2010. doi:10.1016/S0140-6736(09)61965-6 · PMID 20167359
25. Journal / agency FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. 19 March 2010
26. Other Sternberg S. Simvastatin can damage muscles in high doses. 9 June 2011
27. Journal / agency Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clinical Pharmacology and Therapeutics. November 1998. doi:10.1016/S0009-9236(98)90130-8 · PMID 9834039
28. Journal / agency Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. British Journal of Clinical Pharmacology. July 2004. doi:10.1111/j.1365-2125.2004.02095.x · PMID 15206993 · PMC1884539
29. Other Cholesterol-lowering medicines, statins - Interactions. 16 April 2012
30. Journal / agency Lilja JJ, Kivistö KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clinical Pharmacology and Therapeutics. October 2000. doi:10.1067/mcp.2000.110216 · PMID 11061578
31. Journal / agency Information on Simvastatin/Amiodarone. 8 August 2008
32. Journal / agency Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. American Journal of Cardiovascular Drugs. 2010. doi:10.2165/1158822-S0-000000000-00000 · PMID 21391729
33. Journal / agency Roy A, Jana M, Kundu M, Corbett GT, Rangaswamy SB, Mishra RK, Luan CH, Gonzalez FJ, Pahan K. HMG-CoA Reductase Inhibitors Bind to PPARα to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice. Cell Metabolism. August 2015. doi:10.1016/j.cmet.2015.05.022 · PMID 26118928 · PMC4526399
34. Journal / agency Zocor- simvastatin tablet, film coated. 9 August 2023
35. Other Li JJ. Triumph of the Heart: The Story of Statins. 2009
36. Journal / agency Endo, Akira. A historical perspective on the discovery of statins. Proceedings of the Japan Academy, Series B. 2010. doi:10.2183/pjab.86.484 · PMID 20467214 · PMC3108295
37. Journal / agency Liao JK, Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology. 2005. doi:10.1146/annurev.pharmtox.45.120403.095748 · PMID 15822172 · PMC2694580
38. Other Williams O, Jacks AM, Davis J, Martinez S. Innovation Management - Strategies, Implementation, and Profits. 1998
39. Journal / agency Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews. Drug Discovery. July 2003. doi:10.1038/nrd1112 · PMID 12815379
40. Journal / agency Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. November 1994. doi:10.1016/S0140-6736(94)90566-5 · PMID 7968073
41. Other Berenson A. Merck Loses Protection for Patent on Zocor. 23 June 2006
42. Other PPACA no cost-share preventive medications
43. Journal / agency Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement. American Family Physician. 15 January 2017
44. Other Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. 15 November 2016
45. Other Merck gets Zocor patent extension. 3 November 2002
46. Other About simvastatin. 10 February 2022
47. Journal / agency Mayor, Susan. Drug regulator criticised for error in reporting consultation results. BMJ (Clinical Research Ed.). 18 June 2005. doi:10.1136/bmj.330.7505.1410 · PMID 15961813 · PMC558369
48. Journal / agency Meek, C. UK decision to sell statins over the counter criticized. Canadian Medical Association Journal. 7 June 2005. doi:10.1503/cmaj.050532 · PMC558157

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.